Michalaki, Vasiliki <br/><br/>
Trastuzumab plus capecitabine and docetaxel as first-line therapy for HER2-positive metastatic breast cancer: phase II results.  [electronic resource] 

 -  Anticancer research  Jul 2010 
 - 3051-4 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article 
<br/><br/><label>ISSN: </label>1791-7530 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Humanized<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Breast Neoplasms--drug therapy<br/>Capecitabine<br/>Deoxycytidine--administration & dosage<br/>Disease-Free Survival<br/>Docetaxel<br/>Female<br/>Fluorouracil--administration & dosage<br/>Humans<br/>Middle Aged<br/>Neoplasm Metastasis<br/>Prospective Studies<br/>Receptor, ErbB-2--biosynthesis<br/>Receptors, Estrogen--biosynthesis<br/>Receptors, Progesterone--biosynthesis<br/>Taxoids--administration & dosage<br/>Trastuzumab